Descartes-25 in Relapsed/Refractory Multiple Myeloma

Last updated: November 8, 2024
Sponsor: Cartesian Therapeutics
Overall Status: Terminated

Phase

1

Condition

Lymphoproliferative Disorders

Bone Neoplasm

Cancer/tumors

Treatment

Descartes-25

Clinical Study ID

NCT05113342
DC25-1A
  • Ages > 18
  • All Genders

Study Summary

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years and older'

  • diagnosed with active R/RMM, who have failed 2 lines of treatment

  • have measurable disease

Exclusion

Exclusion Criteria:

  • Patients with active plasma cell leukemia

Study Design

Total Participants: 9
Treatment Group(s): 1
Primary Treatment: Descartes-25
Phase: 1
Study Start date:
November 25, 2021
Estimated Completion Date:
November 08, 2024

Connect with a study center

  • Saglik Bilimleri Universitesi

    Ankara, Anatolia 06200
    Turkey

    Site Not Available

  • Louisiana State University Health Science Center at Shreveport

    Shreveport, Louisiana 71103
    United States

    Site Not Available

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland 20817
    United States

    Site Not Available

  • Medical College of Wisconsin

    Madison, Wisconsin 53226
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.